Background: Fucoidan, an antithrombotic polysaccharide, can induce endothelial colony-forming cells (ECFC) to adopt an angiogenic phenotype in vitro. Objectives: We evaluated the effect of fucoidan on vasculogenesis induced by ECFC in vivo. Methods: We used a murine hindlimb ischemia model to probe the synergic role of fucoidan-treatment and ECFC infusion during tissue repair. Results: We found that exposure of ECFC to fucoidan prior to their intravenous injection improved residual muscle blood flow and increased collateral vessel formation. Necrosis of ischemic tissue was significantly reduced on day 14, to 12.1% of the gastronecmius cross-sectional surface area compared with 40.1% in animals injected with untreated-ECFC. ECFC stimulation with fucoidan caused a rapid increase in cell adhesion to activated endothelium in flow conditions, and enhanced transendothelial extravasation. Fucoidan-stimulated ECFC were resistant to shear stresses of up to 21 dyn cm
INTRODUCTION
Cardiovascular disease, due essentially to atherosclerosis, causes about half of all deaths in western countries. Peripheral vascular disease of the lower limbs is characterized by chronic obstruction of the arteries supplying the leg, gradually leading to critical limb ischemia. In endstage disease, severe hypoperfusion results in ischemic ulceration and gangrene, with a high risk of amputation (10 to 40%) the first years [1] . Limb loss is best prevented by revascularization with endovascular or surgical approaches but this is impossible in 30% of patients with critical limb ischemia. No medical treatments have been shown to reduce the amputation rate at 6 months [2] . In this context, activation of local angiogenesis is a promising approach.
Infusion of in vitro-expanded bone marrow progenitor cells can enhance neovascularization in
animal models of hindlimb ischemia [3, 4] . Among these cells, endothelial progenitor cells are involved in regeneration of injured endothelium and neoangiogenesis after tissue ischemia, and are therefore a candidate cell therapy product [3, 5, 6] . Different cell populations have been isolated which play a role in angiogenesis, but only one population, called "endothelial colonyforming cells" (ECFC) have been shown to possess all the characteristics of true endothelial progenitor and to form neovessel in vivo [3, 4, 7, 8] . However, proangiogenic approaches to critical limb ischemia have so far given disappointing results, owing partly to insufficient homing and survival of transplanted progenitor cells at the ischemic site [2, [9] [10] [11] [12] [13] . The ability of these cells to mobilize and migrate to ischemic sites appears to be an important factor in the success of such therapy [3, 9, 14, 15] . Proangiogenic potential can be enhanced by activating ECFC prior to their injection and thereby amplifying the biochemical signalling cascades that contribute to the production of cytokines involved in the neovascularization process [3, 4, 6, [16] [17] [18] . Sarlon et al Proangiogenic role of fucoidan in vivo 5 We have previously reported that fucoidan enhances the proangiogenic properties of ECFC in vitro [19] . Fucoidan is a marine sulphated polysaccharide with antithrombotic properties which contrary to heparin does not significantly increase the bleeding risk, as it has a lower capacity to activate antithrombin [20] . Like proteoglycans, fucoidan interacts with a wide range of proteins and thus exhibit other biological properties including anti-inflammatory activity. It may act as a regulator of tissue remodelling [21] and has been shown to promote neovascularization when infused intramuscularly, together with the proangiogenic growth factor FGF-2, in a rat model of hindlimb ischemia [20, 22] . Here we studied the interaction of fucoidan with infused ECFC during functional neovascularization in an athymic nude mouse model of hindlimb ischemia. We also investigated the mechanisms by which fucoidan enhances angiogenesis.
METHODS

Cell culture, characterization and pretreatment
Endothelial cells from human umbilical cords (HUVEC) and ECFC from human umbilical cord blood collected from consenting mothers (n=20), were isolated, expanded and characterized as previously described [19] . The study was approved by local ethics committee of "Hôpital des
Instructions et des Armées de Begin" (201008043234797) and protocol conformed to ethical guidelines of Declaration of Helsinki. Flow cytometry was used to assess cell surface antigen expression of the endothelial lineage [18] . One day before all experiments, cells were growtharrested for 24h in EBM-2, 2% FCS and released from growth arrest by adding EBM-2, 5% FCS, with or without 10µg/ml of fucoidan concentrations for 24h or 72h at 37°C, then washed, detached with versene/0.01% collagenase (1/1) and washed twice with buffered Hank's, 0.5%
BSA before use in angiogenesis and adhesion assays as previously described [18] . Supernatants 
Mouse model of hindlimb ischemia
Animal care conformed to French guidelines (Services Vétérinaires de la Santé et de la Production Animale). The experiments were approved by the IDF Paris Institutional Research
Ethics Committee (CREEA, P2.CBV.031.07). Unilateral hindlimb ischemia was induced by femoral artery ligation in seven-week-old male athymic nude mice (Harlan) as previously described [18] . Five hours later the animals received an intravenous injection of normal saline (n=10), ECFC (10 5 cells per animal; n=10) or ECFC incubated in starvation medium overnight then stimulated with fucoidan 10µg/ml for 24 h, and washed (10 5 cells per animal; n=10). To evaluate the effect of fucoidan on critical ischemia, 3 groups of animals underwent the surgical procedure and received two intramuscular injection 1 and 2 days after surgery of normal saline, fucoidan solution (15mg/kg) or low molecular weight heparin (Lovenox, Sanofi Advantis, 2.5mg/kg). Laser Doppler perfusion imaging (Perimed, France) was used to appreciate revascularisation on day 14 [18] . Hindlimb macroscopic necrosis was quantified before sacrifice as previously described [23] . A score was calculated for each animal, as follows: 0: no necrosis, 1: necrosis of one toe, 2: necrosis of two or more toes, 3: foot necrosis, 4: leg necrosis and 5:
autoamputation of the entire leg. Vessel density was evaluated by high-definition microangiography (Trophy system) and was expressed as the ratio of the ischemic to non ischemic leg percentage of pixels per image in the quantification area occupied by vessels [18] .
Peripheral venous blood samples were collected 14 days after surgery. 
Computed-assisted histomorphometric analysis
The gastronecmius muscles from both hindlimbs were fixed in 4% formol and embedded in paraffin. Histological studies were based on computed-assisted analysis of different area (ICS framework viewer, Tribvn) as previously described [12] . For each muscle, four sections 4µm thick and 300µm apart were stained with H&E then digitized for further analysis. The mean of surface area of each tissue type (necrotic, ischemic or healthy) was quantified in each muscle and reported as a percentage of the entire surface area of the section (n=4). The ratio between the mean entire cross-sectional areas of the ischemic and non ischemic gastronecmius muscles in each animal was used as an index of muscular trophicity.
Shear-flow adhesion assays
Tethering, rolling and flow adhesion experiments were conducted with a parallel-plate flow chamber in physiological shear stress conditions as previously described [18] . To distinguish between the adhesion of pretreated ECFC and that of detached endothelial cells, ECFC were stained with calcein. HUVEC monolayers (7.5 10 5 ) were grown on coverslips, maintained at 37°C for 6 days, then placed in the flow chamber and stimulated by exposure to a shear rate of 0.4 dyn/cm 2 for 30min. Calcein-labeled ECFC in adhesion buffer (cation-free HBSS, 10 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, 2 mg/ml BSA, pH 7.4) were then perfused for 15min at 37°C at a shear rate of 0.4 dyn/cm 2 and the coverslips were washed with adhesion buffer for 10min. Adherent cells were visualized by phase-contrast microscopy. All experiments were performed in real time and videotaped for offline analysis. Images from 60 random microscope 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Detachment of adherent ECFC was studied by increasing the flow rate from 0.4 to 22 dyn/cm 2 . In some experiments, fucoidan-stimulated or untreated ECFC were pretreated for 2h at 37°C with 0.5 U/ml heparinase I, 0.1 U/ml heparinase III and 0.2 U/ml chondroitinases ABC (Sigma).
Rat aortic ring assay
Angiogenesis was also studied with aortic explants cultured in three dimensional matrix gels as described by Zhu et al [24] . Experiments conformed to the guidelines of the University ParisDescartes Institutional Animal Care and Use Committee (C75.06.02). The thoracic aorta was isolated from 8-week-old male Wistar rats (Charles River Breeders), immediately transferred to a culture dish containing warm serum-free minimum essential medium, and sliced into 1 to 2mm rings after carefully removing fibroadipose tissue. The aortic rings were rinsed and embedded in rat tail type I collagen gel. The gels were overlaid with DMEM-10% FCS supplemented with 100 U/ml penicillin and 100µg/ml streptomycin. Fucoidan (10µg/ml), FGF-2 (50ng/ml) or VEGF (40ng/ml) was added to the medium in the appropriate wells. The medium was changed on days 3, 6 and 9 of culture. Angiogenesis was scored by counting the number of branching endothelial sprouts.
Statistical analysis
Data are expressed as means ± SEM of at least three independent experiments. Significant differences were identified by ANOVA 
RESULTS
Having previously shown that fucoidan can induce ECFC to adopt a proangiogenic phenotype in vitro [19], we first assessed the ability of fucoidan-stimulated ECFC to promote neovascularization in a mouse model of hindlimb ischemia. We focused on ECFC because this cell type is currently proposed as the cell type at the origin of newly formed vessels [7] . Cells were isolated from human umbilical cord blood on the basis of CD34 expression. The presence of Weibel-Palade bodies and combined expression of endothelial markers (CD31,Tie-2,KDR,Flt-1,CD144) unequivocally confirmed the endothelial phenotype of the ECFC thus obtained.
Furthermore ECFC do not express leuko-monocytic markers such as CD14 and CD45 [18] .
Mice treated with fucoidan-stimulated ECFC are protected from ischemia-induced necrosis.
Respectively 30% and 25% of mice that received normal saline or untreated ECFC exhibited macroscopic necrosis ( Figure 1A) . No mice treated with fucoidan-stimulated ECFC had macroscopic necrosis (p<0.05 vs CTRL, n=10).
Fucoidan-stimulated ECFC enhance post-ischemic neovascularization.
Hindlimb perfusion was respectively 34% and 99% higher with fucoidan-stimulated ECFC than with untreated ECFC (p<0.001) and normal saline (p<0.001) ( Figure 1B) . The ischemic/non ischemic limb angiography score was 11% higher with fucoidan-stimulated ECFC than with untreated ECFC, but the difference was not statistically significant ( Figure 1C ).
Fucoidan-stimulated ECFC protect ischemic tissue against necrosis.
The results of histomorphometric analysis of distal gastronecmius muscle sections on day 14 in mice treated with normal saline, control ECFC and fucoidan-stimulated ECFC are shown in Figure 2 . Digitized muscle sections were divided into three areas: i) preserved areas with a Figure 2C) , ii) ischemic areas containing cellular alterations but no necrosis ( Figure 2D ) and iii) necrotic tissue with muscle cell destruction ( Figure 2E ). Animals treated with fucoidan-stimulated ECFC showed less necrosis (p<0.01, Figure 2E ) and better muscle preservation than animals treated with control ECFC (p<0.05, Figure 2C ) or with saline solution alone (p<0.01, Figure 2C ).
CELLULAR AND MOLECULAR MECHANISMS INVOLVED IN FUCOIDAN ENHANCEMENT OF PROANGIOGENIC ACTIVITY.
We next examined the potential mechanisms by which fucoidan-stimulation improved proangiogenic properties of ECFC. We investigated whether ECFC stimulation with fucoidan enhances their homing to ischemic tissue via ECFC adhesion to activated endothelium, their extravasation and differentiation into a vascular network.
Fucoidan-stimulated ECFC show enhanced adhesion to activated HUVEC in flow conditions.
We used a flow-based adhesion assay with HUVEC to investigate the effect of fucoidan stimulation on treated ECFC adhesion to activated endothelium in conditions simulating the shear forces encountered by ECFC when they adhere to vascular endothelial cells. In our experimental conditions, fucoidan-stimulated ECFC adhered much more rapidly than control ECFC. As shown in Figure 3A , short ECFC exposure to fucoidan caused a rapid increase in adhesion to HUVEC (1000 treated cells/cm 2 versus 545 control cells/cm 2 ; p<0.001). Fucoidan-stimulated ECFC adhered firmly to the endothelium and were more resistant than control cells to washing at shear rates up to 21 dyn/cm 2 ( Figure 3B ). This property is not correlated to fucoidan stimulation on cell surface integrins α L β2 (LFA-1), α M β2 (MAC-1) or α4β1 (VLA4) expression levels and gene expression (data not shown). 
Bound fucoidan acts as a glycosaminoglycan
Because fucoidan is a sulphated polysaccharide and as heparan-sulphate proteoglycans (HSPG) play key roles in the angiogenic process, presenting chemokines to circulating cells, we investigated the role of fucoidan bound to the ECFC surface in ECFC adhesion and differentiation processes. ECFC were treated for 120 min with enzymes that selectively degrade either heparan sulphate or chondroitin sulphate, and were then incubated with 10 µg/ml fucoidan at 37°C overnight. Enzyme treatment abolished ECFC adhesion to the endothelium in flow conditions (-65% p<0.001; Figure 3A ) and also reduced tube formation in Matrigel (-50%, poor resistance to detachment when tested at shear stresses up to 20 dyn/cm 2 ( Figure 3B ). This fucoidan pretreatment had no effect on HSPGd-ECFC extravasation or tube formation (data not shown).
Fucoidan promotes angiogenesis in the aortic ring model.
Rings of rat aorta embedded in collagen gel immediately after excision generate branching microvessels, and this process was enhanced by FGF-2 and VEGF in a concentration-dependent manner, as previously reported [24] . Unstimulated control rings exhibited only rare and short endothelial sprouts. As shown in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Fucoidan protects ischemic tissue against necrosis better than heparin.
Histomorphometric analysis of distal gastronecmius muscle sections on day 14 in mice treated with intramuscular injection of normal saline, low molecular weight heparin (2.5 mg/kg) and fucoidan (15mg/kg) are shown in Figure 6 . Animals treated with fucoidan showed less necrosis and better muscle preservation than animals treated with saline solution alone and heparin treated animals (p<0.001 and p<0.01 respectively, Figure 6A -C). This correlates with significant decrease of blood levels of CPK 14 days after surgery ( Figure 6D ). Serum CPK and LDH are enzymes whose levels can increase significantly when muscle damage or inflammation has occurred. In the control animals, a serum CPK activity of 2200 ± 600 UI -1 was observed.
Fucoidan pretreatment markedly attenuated the CPK activity (≈70% p=0.002, ≈60% p=0.0320) compared with respectively the control and heparin groups. No significant changes were observed regarding the serum lactate dehydrogenase activity.
DISCUSSION
Fucoidan, an antithrombotic polysaccharide, can induce ECFC to adopt an angiogenic phenotype in vitro [19] . Human ECFC treatment with fucoidan induced proangiogenic phenotype, involving both an early angiogenic event (proliferation and migration) and a late event (differentiation into vascular cords). This study shows that the beneficial effect of ECFC infusion in a mouse model of hindlimb ischemia is amplified significantly by fucoidan pretreatment, preventing necrosis.
This tissue protection is associated with enhanced neoangiogenesis and reduction of rhabdomyolysis. The angiogenic process involves ECFC rolling and adhesion to activated endothelium and their extravasation to target sites. Our results provide strong evidence that fucoidan prestimulation enhanced each of these steps, by inducing pro-MMP-9 secretion involved in cell homing [25] .
These actions were associated with direct fucoidan interaction with the ECFC surface. Fucoidan bound to the cell membrane and was internalized. We have previously shown that fucoidan stimulation leads to ECFC actin cytoskeleton changes, which may be involved in extravasation [19] . Experiments underway in our laboratory indicate that fucoidan interaction is partially inhibited by blocking antibodies against P-selectin, CD11b (α M ) and CD18 (β2) (30 to 40%, p<0.001). This is in keeping with the reported high affinity of selectin and integrin α M β 2 for a high-molecular-weight commercial fucoidan preparation [26, 27] . Because of its spatial structure, fucoidan can mimic the clustering of sulphated, sialylated and fucosylated oligosaccharides on the cell surface and can provide the appropriate structural backbone for selectin binding. Tissue ischemia is also accompanied by inflammation and fucoidan has been shown to possess
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Expanded methods and Methods
Materials
In vitro studies
Preparation and labelling of low-molecular-weight fucoidan.
Low-molecular-weight (LMW) fucoidan was provided by Therapol (France 
Cell culture, characterization and pretreatment
Endothelial cells (HUVEC) and ECFC were isolated from respectively the human umbilical cords and from the human umbilical cord blood of healthy consenting mothers (n=20), by density-gradient centrifugation with Histopaque-1077 (Sigma-Aldrich; France) as previously 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Real-time (RT) polymerase chain reaction
Total RNA was extracted either directly with the RNABle® technique (Eurobio GEXEXTOO-OW) or following pre-treatment with fucoidan (10µg/ml) for 4 and 24 hours.
Total RNA (250ng/µl) was reverse-transcribed. Transcripts of the TBP gene, an endogenous RNA control coding for the TATA box-binding protein, were quantified and target gene 
In vitro angiogenesis assays
Cell adhesion, transendothelial migration and matrigel tube formation were measured as previously described [Zemani F Arterioscler Thromb Vasc Biol. 2008,28:644-650] . Gelatin zymography of culture medium conditioned by fucoidan-treated and untreated ECFC was performed as described elsewhere [Senni K et al. Arch Biochem Biophys. 2006,445:56-64 ].
HT1080 cell conditioned medium was used as standard. This established cell line constitutively releases proMMP-2 (72kDa) and proMMP-9 (92kDa) into the culture medium.
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